Candida utilis as an emerging rare cause of septicemia among neonates and children in Western Uttar Pradesh: A case series.

Q3 Medicine
Current Medical Mycology Pub Date : 2024-05-07 eCollection Date: 2024-01-01 DOI:10.22034/cmm.2024.345218.1529
Dharmendra Prasad Singh, Rajesh Kumar Verma, Rajesh Kumar Yadav, Ketan Anant, Anupam Das
{"title":"<i>Candida utilis</i> as an emerging rare cause of septicemia among neonates and children in Western Uttar Pradesh: A case series.","authors":"Dharmendra Prasad Singh, Rajesh Kumar Verma, Rajesh Kumar Yadav, Ketan Anant, Anupam Das","doi":"10.22034/cmm.2024.345218.1529","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong><i>Candida utilis</i> is a recently emerging nosocomial fungal pathogen. Candidemia is the fourth most prevalent cause of bloodstream Infections with mortality rates varying from 5-71%.</p><p><strong>Materials and methods: </strong>This was a retrospective study conducted at Uttar Pradesh University of Medical Sciences, Etawah, India, from September 2023 to February 2024. Rapid identification was performed by VITEK® 2 (BioMérieux, France) and 18 out of 20 <i>C. utilis</i> cases were verified by matrix assisted laser desorption ionization-time of flight mass spectrometry (BioMerieux, France). Susceptibility testing was conducted by VITEK® 2 appropriate Card.</p><p><strong>Results: </strong><i>Candida utilis</i> was mainly observed between 0-9-month-old neonates, except one case of 11 years old. The extended Intensive Care Unit stay and prior antibiotic use were common risk factors in all cases. They were pan susceptible to each of the tested antifungal medications, and 6 out of 10 cases showed positive clinical response after antifungal treatment.</p><p><strong>Conclusion: </strong>Early identification and prompt treatment favors a good clinical outcome. The current research primarily aimed to elaborate on the speciation, incidence, and antifungal susceptibility testing of <i>C. utilis</i> at a tertiary care center.</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"10 ","pages":"e2024.345184.1529"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11688595/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Mycology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22034/cmm.2024.345218.1529","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: Candida utilis is a recently emerging nosocomial fungal pathogen. Candidemia is the fourth most prevalent cause of bloodstream Infections with mortality rates varying from 5-71%.

Materials and methods: This was a retrospective study conducted at Uttar Pradesh University of Medical Sciences, Etawah, India, from September 2023 to February 2024. Rapid identification was performed by VITEK® 2 (BioMérieux, France) and 18 out of 20 C. utilis cases were verified by matrix assisted laser desorption ionization-time of flight mass spectrometry (BioMerieux, France). Susceptibility testing was conducted by VITEK® 2 appropriate Card.

Results: Candida utilis was mainly observed between 0-9-month-old neonates, except one case of 11 years old. The extended Intensive Care Unit stay and prior antibiotic use were common risk factors in all cases. They were pan susceptible to each of the tested antifungal medications, and 6 out of 10 cases showed positive clinical response after antifungal treatment.

Conclusion: Early identification and prompt treatment favors a good clinical outcome. The current research primarily aimed to elaborate on the speciation, incidence, and antifungal susceptibility testing of C. utilis at a tertiary care center.

念珠菌作为一个新兴的罕见原因败血症在新生儿和儿童在北方邦西部:一个案例系列。
背景与目的:实用念珠菌是一种新出现的医院真菌病原体。念珠菌是血液感染的第四大流行原因,死亡率在5-71%之间。材料和方法:这是一项回顾性研究,于2023年9月至2024年2月在印度埃塔瓦的北方邦医学大学进行。快速鉴定采用VITEK®2 (BioMerieux, France), 20例C. utilis病例中有18例采用基质辅助激光解吸电离飞行时间质谱法(BioMerieux, France)进行验证。药敏试验采用VITEK®2合适卡。结果:除11岁1例外,以0 ~ 9月龄新生儿为主。在所有病例中,延长重症监护病房住院时间和先前使用抗生素是常见的危险因素。他们对每一种抗真菌药物均敏感,10例患者中有6例抗真菌治疗后临床反应阳性。结论:早期发现,及时治疗,临床效果良好。目前的研究主要旨在阐述在三级保健中心的C. utilis的物种形成,发病率和抗真菌药敏试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Medical Mycology
Current Medical Mycology Medicine-Infectious Diseases
CiteScore
2.10
自引率
0.00%
发文量
16
审稿时长
4 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信